Graves' Orbitopathy Pipeline Outlook Report 2025: Novel Treatments, Clinical Updates, and Market Trends | DelveInsight

DelveInsight's "Graves' Orbitopathy Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Graves' Orbitopathy pipeline landscape. It covers the Graves' Orbitopathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Graves' Orbitopathy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Graves' Orbitopathy Pipeline? Click here to explore the therapies and trials making headlines @ Graves' Orbitopathy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Graves' Orbitopathy Pipeline Report

* On 03 October 2025, Innovent Biologics (Suzhou) Co. Ltd announced a phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease. Approximately 36 subjects meeting the study eligibility criteria will be randomly assigned to the 3-10 mg group, 3-20 mg group, 10 mg group, or 20 mg group on day 1 in a 1:1:2:2 ratio.
* DelveInsight's Graves' Orbitopathy Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Graves' Orbitopathy treatment.
* The leading Graves' Orbitopathy Companies such as Astellas, Jiangsu Hengrui Medicine, Novartis and others.
* Promising Graves' Orbitopathy Therapies such as Teprotumumab, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, IBI311 (20 mg), lonigutamab, Satralizumab, TEPEZZA, LASN01 , and others.

Want to know which companies are leading innovation in Graves' Orbitopathy? Dive into the full pipeline insights @ Graves' Orbitopathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Graves' Orbitopathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Graves' Orbitopathy Pipeline Report also highlights the unmet needs with respect to the Graves' Orbitopathy.

Graves' Orbitopathy Overview

Graves orbitopathy (Graves eye disease or Graves ophthalmopathy) is a constellation of signs and symptoms related to the orbit and surrounding tissues in patients with Graves disease. It can also sporadically occur in patients who are euthyroid or even hypothyroid as a result of chronic thyroiditis. It is an autoimmune process affecting retro-ocular tissues. In its severe form, it can be sight-threatening; thus, prompt evaluation and timely referral and management become of utmost importance. Graves orbitopathy occurs in patients with Graves disease and is an autoimmune disease of retro-ocular tissue.

Graves' Orbitopathy Emerging Drugs

* Linsitinib: Astellas

Linsitinib, which was in-licensed from Astellas Pharma to Sling Therapeutics, is designed to inhibit the insulin-like growth factor I receptor (IGF-1R). Dysfunction in the IGF-1R signaling pathway leads to a prevalence of thyroid-stimulating hormone receptor autoantibodies (TSHR-Abs) that drive excess fibrous tissue growth in TED. Independent data from a model of TED in patient fibroblast cells suggest that linsitinib is at least as potent as currently available treatment. The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for linsitinib for the treatment of TED.Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Graves Orbitopathy.

* SHR 1314: Jiangsu Hengrui Medicine

Vunakizumab (SHR 1314) is being developed by Jiangsu Hengrui Medicine, for the treatment of psoriasis and other autoimmune diseases. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Active Moderate to Severe Graves' Orbitopathy.

If you're tracking ongoing Graves' Orbitopathy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Graves' Orbitopathy Treatment Drugs [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Graves' Orbitopathy Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Graves' Orbitopathy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves' Orbitopathy Treatment.
* Graves' Orbitopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Graves' Orbitopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves' Orbitopathy market.

Graves' Orbitopathy Companies

Astellas, Jiangsu Hengrui Medicine, Novartis and others.

Graves' Orbitopathy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Graves' Orbitopathy Products have been categorized under various Molecule types such as,

* Oligonucleotide
* Peptide
* Small molecule

From emerging drug candidates to competitive intelligence, the Graves' Orbitopathy Pipeline Report covers it all - check it out now @ Graves' Orbitopathy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Graves' Orbitopathy Pipeline Report

* Coverage- Global
* Graves' Orbitopathy Companies- Astellas, Jiangsu Hengrui Medicine, Novartis and others.
* Graves' Orbitopathy Therapies- Teprotumumab, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, IBI311 (20 mg), lonigutamab, Satralizumab, TEPEZZA, LASN01 , and others.
* Graves' Orbitopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Graves' Orbitopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Graves' Orbitopathy Treatment landscape in this detailed analysis @ Graves' Orbitopathy Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Graves' Orbitopathy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Graves' Orbitopathy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase II/III)
* Linsitinib: Astellas
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SHR 1314: Jiangsu Hengrui Medicine
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Graves' Orbitopathy Key Companies
* Graves' Orbitopathy Key Products
* Graves' Orbitopathy- Unmet Needs
* Graves' Orbitopathy- Market Drivers and Barriers
* Graves' Orbitopathy- Future Perspectives and Conclusion
* Graves' Orbitopathy Analyst Views
* Graves' Orbitopathy Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-orbitopathy-pipeline-outlook-report-2025-novel-treatments-clinical-updates-and-market-trends-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/graves-orbitopathy-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.